In this interview with senior science writer and editor, Laura Lansdowne of Technology Networks, our co-founder and CEO Yochi Slonim discusses Anima Biotech’s background, technology platform, and our strategy against previously deemed ‘undruggable’ targets to help underserved patients with hard-to-treat diseases.
In this article by Nikki Withers, our CEO Yochi Slonim discusses how Anima’s drug discovery platform, Translation Control Therapeutics, can track the exact location and rate of protein synthesis for any target protein of interest involved in a disease leveraging FRET light pulses to visualize mRNA translation from within ribosomes. This approach enables the discovery of small molecules that modulate the translation of a target protein as an entirely novel target space to aid in the treatment of undruggable diseases
Anima biotech was named Startup City’s 15 Most Promising Biotech Startups of 2019. In the feature, our CEO Yochi Slonim discusses how Anima’s drug discovery platform, Translation Control Therapeutics, can track the exact location and rate of protein synthesis for any target protein of interest involved in a disease. This piece also examines the current mRNA therapeutics space.
Anima Biotech updates on translation control therapeutics platform, reflects on Lilly partnership October 27th, 2019
Anima Biotech Inc CEO Yochi Slonim caught up with Proactive at the 2019 BIO Investor Forum in San Francisco.
Slonim updated investors on its Translation Control Therapeutics platform and reflected on the company's partnership with Eli Lilly and Company.
In this interview with Gail Dutton in Genetic Engineering & Biotechnology News, our CEO Yochi Slonim discusses Anima Biotech’s novel strategy and approach to the discovery and development of new small molecule drugs that target and control the process of mRNA translation into proteins.
In this deeper dive into how biopharmaceutical companies are approaching translational medicine, our CEO Yochi Slonim and other experts in the industry discuss novel targets in drug discovery and how to increase the number of drugs that can be successfully brought to market.
In this article by Chelsea Weidman Burke, our CEO Yochi Slonim discusses how Anima’s own drug discovery platform, Translation Control Therapeutics, can track the exact location and rate of protein synthesis for any target protein of interest involved in a disease. This piece also examines the current mRNA therapeutics space.
This piece written by Cath O’Driscoll discusses Anima’s new approach to the discovery of small molecule drugs to target previously hard to treat diseases and could lead to safer, more versatile treatments.
Coverage from a panel during the 2019 BIO convention features the leaders and founders of emerging platform companies including our own CEO Yochi Slonim. This article reviews what makes platform players different from other biopharma ventures and how Anima Biotech’s own drug discovery platform works to identify new small molecules that affect protein synthesis.
This video interview with Mike Ward (Pharma Intelligence) at BIO-Europe Spring 2019, showcases Anima Biotech’s novel approach to discover small molecule drugs that regulate and control the process of mRNA translation into proteins.
In this roundtable review, our CEO Yochi Slonim answers the question “What truly novel therapies in the earliest stages of discovery and development do you believe will have a significant impact in the future?” Mr. Slonim describes more traditional approaches to drug discovery and how Anima is opening up an entirely different space of novel targets by finding small molecules that can bind to the proteins that regulate protein translation rather than drugging mRNA or proteins directly.
This feature by Lauren Martz, Associate Editor of BioCentury, covers how Anima Biotech is leveraging its Translation Control Therapeutics platform to purse novel targets of mRNA translation regulators in order to develop tissue selective small molecule drugs.
In this interview with our CEO Yochi Slonim, Mark Terry, contributing writer to BioSpace, examines Anima Biotech’s unique approach to mRNA therapeutics and its high throughput screening technology platform to identify small molecules that can decrease or increase mRNA translation into proteins.
This radio interview recorded at the BIO CEO and Investor Conference in 2019 describes Anima Biotech’s business model and Translation Control Therapeutics platform for the discovery and development of small molecule drugs that target proteins that control mRNA translation into proteins.
In this video, learn how Anima Biotech’s Translation Control Therapeutics platform technology can visualize the protein synthesis process allowing scientists to gain insights in the mechanisms of a disease and discover new drugs that control protein translation.
Eli Lilly & Co. and Anima Biotech win US Deal of the Year at Lifestars Awards 2018 November 15th, 2018
In this video interview with Tim Luker, Senior Director, Emerging Technology & Innovation at Eli Lilly & Co., describes what the collaboration with Anima Biotech and the potential of Anima’s Translation Control Therapeutics technology means to the future of drug discovery at Eli Lilly.
This company profile, written by Jo Shorthouse, establishes Anima Biotech as a leader in the translation biology space with its technology for the discovery and development of small molecule drugs that control and regulate protein synthesis.
In a company examination, this article describes the therapeutic potential of Anima Biotech’s Translation Control Therapeutics technology in the discovery of small molecules that control protein translation.